Humanigen CEO to Present at 8th Annual LD Micro Invitational

May 30, 2018

BURLINGAME, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments, today announced that Cameron Durrant, M.D., chairman and CEO, will present a company overview at the 8th Annual LD Micro Invitational on Monday, June 4, 2018, at 4 p.m. PDT (7 p.m. EDT).

Dr. Durrant will discuss Humanigen’s focus to enhance T-cell therapies in oncology with its proprietary Humaneered® monoclonal antibodies, including lead asset lenzilumab as a potential prophylactic therapy to optimize treatment and minimize or prevent neurotoxicity associated with chimeric antigen receptor T-cell (CAR-T) therapy. Lenzilumab is a first-inclass recombinant monoclonal antibody that targets and is an antagonist of soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), an upstream druggable target for inflammatory cascade side effects caused by CAR-T treatments.

A live webcast of the presentation will be available at Following the conference, an archived version of the webcast will be available 120 days for replay on the Humanigen website at

For more information on the conference, please visit

About Humanigen

Humanigen, Inc. is a biopharmaceutical company developing cutting-edge T-cell optimization and oncology treatments. Derived from the company’s Humaneered® platform, lenzilumab, ifabotuzumab and HGEN005 are monoclonal antibodies with first-inclass mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential medicine to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Eph receptor A3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, as well as a backbone for a novel CAR-T construct and bispecific antibody platform. HGEN005, which targets human epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1), has potential as a treatment for eosinophilic diseases, such as a novel CAR-T construct for eosinophilic leukemia. For more information, visit

Source: Humanigen, Inc.

Released May 30, 2018

  • Twitter

©2020 Humanigen, Inc.  All rights reserved